Cargando…
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for th...
Autores principales: | Titanji, Boghuma K, Farley, Monica M, Mehta, Ashish, Connor-Schuler, Randi, Moanna, Abeer, Cribbs, Sushma K, O’Shea, Jesse, DeSilva, Kathryn, Chan, Bonnie, Edwards, Alex, Gavegnano, Christina, Schinazi, Raymond F, Marconi, Vincent C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337637/ https://www.ncbi.nlm.nih.gov/pubmed/32597466 http://dx.doi.org/10.1093/cid/ciaa879 |
Ejemplares similares
-
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019
(COVID-19) Coagulopathy? Jorgensen et al
por: Titanji, Boghuma K, et al.
Publicado: (2020) -
Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
por: Titanji, Boghuma, et al.
Publicado: (2020) -
Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality
por: Mehta, Puja, et al.
Publicado: (2022) -
Reply to Jorgensen, et al
por: Titanji, Boghuma K, et al.
Publicado: (2020) -
Vaxxing to elimination: smallpox vaccines as tools to fight mpox
por: Titanji, Boghuma K., et al.
Publicado: (2023)